OMT Presents Breakthrough In Novel Human Antibody Platform Development

Anonymous User | Login

OMT Presents Breakthrough In Novel Human Antibody Platform Development

Published: 23-Jul-2009

A critical milestone, creation of rats with permanent, heritable genetic mutations

Open Monoclonal Technology (OMT), in collaboration with Sangamo BioSciences, Sigma-Aldrich, Medical College of Wisconsin, and INSERM, has created the first targeted knockout rats as detailed in Knockout Rats Produced via Embryo Microinjection of Designed Zinc Finger Nucleases.

The creation of rats with permanent, heritable genetic mutations is a critical milestone in the development of OMT’s novel human monoclonal antibody platform, said the company.

Roland Buelow, CEO of OMT, said: Creating a knockout rat was the biggest challenge OMT faced. Inactivation of endogenous rat antibody expression is essential for human antibody expression in genetically engineered animals. To solve this problem, we explored a new application for Zinc Finger Nuclease (ZFN) technology, which enabled a technique that could revolutionize the genetic engineering of animals.

US Department of Agriculture Grants Approval For Bayer’s GlyTol Cotton Technology

Following the approval from the US Food and Drug Administration (FDA), the US Department of Agriculture (USDA) has also approved Germany-based Bayer CropSciences' GlyTol ...

Sangamo' Positive Phase-II Results For ZFP Therapeutic Program

Shows dual angiogenic and neurotrophic effects of SB-509 for later stages of DN ...

OraSure Provides Update On Clinical Development Programs

Filed PMA with FDA for approval of OraQuick HCV test, for use in professional market ...

Millipore, Proteome Sciences Sign Licensing Agreement

To develop innovative research tools to advance the study of Alzheimer's disease ...

BioTime Signs Stem Cell Co-marketing Agreement With Millipore

To make cell lines widely available to scientists worldwide, allowing them to more quickly perform the R&D work that may lead to life-saving therapies ...

Bayer Receives FDA's Complete Response Letter For Rivaroxaban

Bayer has received a complete response letter from the US Food and Drug Administration (FDA) for its new drug application (NDA), rivaroxaban. The new drug will be used fo ...

Bayer, Onyx Initiates Phase-III Trial Of Nexavar In NSCLC

Bayer and Onyx have started enrolling patients in an international Phase-III trial to evaluate Nexavar (sorafenib) tablets in patients with non-squamous non-small cell lu ...

Onyx Files Complaint Against Bayer

Onyx Pharmaceuticals has filed a complaint against Bayer Corporation and Bayer A.G., in the District Court of California, claiming its rights to a Phase 2 anti-cancer com ...

BioTime Signs Stem Cell Co-marketing Agreement With Millipore

To make cell lines widely available to scientists worldwide, allowing them to more quickly perform the R&D work that may lead to life-saving therapies ...

Millipore, Proteome Sciences Sign Licensing Agreement

To develop innovative research tools to advance the study of Alzheimer's disease ...

Network Sites

Contract Research Clinical Trials Contract Services Drug Delivery Drug Discovery & Development OTC Regulatory Affairs Process and Production IT and Software Laboratory Instrumentation Manufacturing Fine & Specialty Chemicals Medical Devices Business Review Inward Investment Packaging

Mail sent successfully

Tell your friend about this article

Please enter a valid email address

Please enter your name

Please enter the mail body

Your Name: *

Your Email: *

Friend's Email: *

Email Body: *: I thought you would be interested in this article : http://www.pharmaceutical-business-review.com/news/omt_presents_breakthrough_in_novel_human_antibody_platform_development_090723/

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Almac

Drug Development Solutions ...

STARLIMS

Benefits for Life Science Labs ...

Parenteral Drug Association (PDA)

Pharmaceutical Information and Education Services ...

Burkert Fluid Control Systems

Fluid and Gas Control Systems ...

IMCOR

LIMS and Laboratory Informatics Consultancy ...

Umicore Precious Metals Chemistry

Chemicals and Catalysts for Industrial Applications ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Related Companies

Sigma-Aldrich Corporation

Sigma-Aldrich Corporation (Sigma-Aldrich) is a Life Science and High Technology company ...

Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. (Sangamo) is a developmental stage biotechnology company enga ...

Emergent BioSolutions Inc.

Emergent BioSolutions Inc. (Emergent BioSolutions) is a biopharmaceutical company engag ...

Meridian Bioscience, Inc.

Meridian Bioscience, Inc. (Meridian) is an integrated life science company engaged in m ...

OraSure Technologies, Inc.

OraSure develops, manufactures and markets oral fluid specimen collection devices, diag ...

Suppliers Product News

Almac Completes Phase One of Its Expansion Plan to Pharma Services Facilities

New $15m facility will "meet growing business need for its integrated product development and commercial services."

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750